Tonix Pharmaceuticals Holding Corp (TNXP)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $58.49M
Last updated: Nov 17, 2026 at 11:06 AM ET
Performance (10Y)
Upcoming Estimates
Key Metrics
Technical Indicators Dashboard
As of Nov 16, 2026, the price is 61.7% below its 50-day moving average, and the 50-day average is below the 200-day average. The 14-day RSI is 11.0, below 30, the oversold line.
Moving Averages
MACD
ADX
Aroon & PSAR
Bollinger Bands
RSI (14-Day)
Momentum Oscillators
Volatility Measures
Volume Flow
Volume Metrics
Pivot Points
Advanced Oscillators
Financial Performance
Related GNG Research
No research available
Be the first to write about TNXP
GNG News
All TNXP newsNews
TNXP Valuation
TNXP Profitability: Margins, ROIC and FCF
Tonix Pharmaceuticals Holding (TNXP) has a gross margin of 89.3%, an operating margin of -436.2% and a net margin of 0.0%. It posts a -395.0% FCF margin.
- Gross margin
- 89.3%
- Operating margin
- -436.2%
- Net margin
- 0.0%
- ROE
- -84.1%
- FCF margin
- -395.0%
- FCF yield
- -320.2%
Tonix Pharmaceuticals Holding Competitors
The companies most similar to Tonix Pharmaceuticals Holding (TNXP) include Tenax Therapeutics, Grace Therapeutics and Mink Therapeutics.
Sector: Healthcare
Companies most similar to Tonix Pharmaceuticals HoldingTNXP Analyst Ratings
Tonix Pharmaceuticals Holding (TNXP) has a Buy consensus from 4 analysts: 4 Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell.
- Consensus
- Buy
- Analysts
- 4
- Strong Buy
- 0
- Buy
- 4
- Hold
- 0
- Sell
- 0
- Strong Sell
- 0
TNXP Bull Case vs Bear Case
Bull case
- TNXP grew quarterly revenue 423.8% year over year.
Bear case
- TNXP beat EPS estimates in 25.0% of its last 8 reported quarters.
TNXP Earnings: Beat Rate and Next Report
Tonix Pharmaceuticals Holding (TNXP) beat the EPS estimate in 2 of the last 8 quarters (25.0%). Its next report is expected on Mar 10, 2027.
- Beat rate
- 2 of 8 quarters (25.0%)
- Average surprise
- -41.0%
- EPS estimate (fiscal period ending Dec 31, 2026)
- -$2.41
TNXP Earnings Date
TNXP reports Mar 10, 2027. The date is estimated.
TNXP Earnings Call
The latest TNXP earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptTNXP ETF Holders
GNG tracks 5 ETFs that hold TNXP. The largest weights:
- Fidelity Enhanced Small Cap Core ETF (FESM), 0.02% of the fund
- iShares Russell 2000 ETF (IWM), 0.01% of the fund
- Vanguard Total Stock Market Index Fund Admiral Shares (VTSAX), <0.01% of the fund
- Vanguard Morningstar Total Stock Market ETF (VTI), <0.01% of the fund
- Vanguard Russell 2000 Index Fund ETF Shares (VTWO), <0.01% of the fund
Updated Nov 9, 2026. Built from end-of-day prices, company filings and consensus analyst estimates. Methodology
Frequently Asked Questions About TNXP
When does TNXP report earnings?
Tonix Pharmaceuticals Holding Corp (TNXP) is expected to report earnings on Mar 10, 2027.
Does TNXP pay dividends?
Tonix Pharmaceuticals Holding Corp (TNXP) does not currently pay a regular dividend.
What is TNXP's market cap?
Tonix Pharmaceuticals Holding Corp (TNXP) has a market capitalization of $58.49M with a current stock price of $2.88.
TNXP pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors
Get full access to GNG Research
Create a free account to access portfolio tracking, advanced tools, and more.